Genomatica and Braskem have been successfully producing butadiene at lab scale since June 2015, using their direct, bio-based process. The companies are jointly developing a commercial process for the on-purpose production of butadiene made from renewable feedstocks, as announced in December 2013.
Butadiene is a raw material used in the production of rubber for tyres, as well as for electrical appliances, footwear, plastics, asphalt, building materials, and latex. The demand for butadiene is over 20 billion pounds per year worldwide, and growing. By producing a renewable butadiene, the everyday products made with it, like tyres, can become more sustainable, with a smaller environmental footprint.
Program results include:
- Direct, continuous production: The program team has successfully developed a microorganism that consumes sugar and converts it to butadiene at lab scale, in two-liter fermenters. Butadiene has been produced, collected and measured continuously, over the course of multiple days for each fermentation.
- Development of multiple direct pathways and novel enzymes: To develop an optimal process, Genomatica used its computational tools to figure out every possible way that a microorganism could theoretically make butadiene, and identified 60 potential biological pathways. The five best were selected for experimental validation, conducted by Genomatica and Braskem teams in San Diego and Campinas, along with full-time visiting scientists from Braskem at Genomatica’s Innovation Center. The team explored a large number of enzyme candidates, applying environmental sampling and metagenomics, for each step in the potential pathways. Genomatica then multiplied enzyme activity 60-fold on non-native substrates using its high-throughput screening and enzyme engineering capabilities.
- More intellectual property: The program team has significantly added to the extensive intellectual property that Braskem and Genomatica have in this field. This work speaks to design of optimal microorganisms and processes; supports subsequent development stages; and represents an important competitive advantage.
“Our joint team has made good use of Genomatica’s integrated bioengineering platform, including its computational techniques and high-throughput cloning and screening, to quickly hit a key milestone,” said Nelson Barton, Senior Vice President R&D, Genomatica. “Our ‘rational’ approach to strain design should enable faster, more predictable scale-up and better economics as we advance the program.”
“We’re delighted to share this strong technical progress,” said Patrick Teyssonneyre, Innovation and Technology Director, Braskem. “This sets a foundation for an important new process for the industry. The work we are doing with Genomatica is another example of the success of our open innovation system, which aims to provide our customers with competitive advantages in their businesses. We believe that renewable chemistry is an important part of their future and ours.”